0001354457-18-000271.txt : 20180719
0001354457-18-000271.hdr.sgml : 20180719
20180719090405
ACCESSION NUMBER: 0001354457-18-000271
CONFORMED SUBMISSION TYPE: 25-NSE
CONFIRMING COPY:
PUBLIC DOCUMENT COUNT: 2
FILED AS OF DATE: 20180719
DATE AS OF CHANGE: 20180719
SUBJECT COMPANY:
COMPANY DATA:
COMPANY CONFORMED NAME: ARGOS THERAPEUTICS INC
CENTRAL INDEX KEY: 0001105533
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 562110007
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 25-NSE
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35443
BUSINESS ADDRESS:
STREET 1: 4233 TECHNOLOGY DR
CITY: DURHAM
STATE: NC
ZIP: 27704
BUSINESS PHONE: 9192876300
MAIL ADDRESS:
STREET 1: 4233 TECHNOLOGY DR
CITY: DURHAM
STATE: NC
ZIP: 27704
FORMER COMPANY:
FORMER CONFORMED NAME: MERIX BIOSCIENCE INC
DATE OF NAME CHANGE: 20000207
FILED BY:
COMPANY DATA:
COMPANY CONFORMED NAME: The Nasdaq Stock Market LLC
CENTRAL INDEX KEY: 0001354457
IRS NUMBER: 521165937
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 25-NSE
BUSINESS ADDRESS:
STREET 1: One Liberty Plaza
CITY: New York
STATE: NY
ZIP: 10006
BUSINESS PHONE: 301-978-4144
MAIL ADDRESS:
STREET 1: Office of General Counsel
STREET 2: 805 King Farm Blvd.
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
25-NSE
1
primary_doc.xml
X0203
0001354457
The Nasdaq Stock Market LLC
0001105533
ARGOS THERAPEUTICS INC
001-35443
4233 Technology Drive
Durham
NC
NORTH CAROLINA
27704
919-287-6300
Common Stock
17 CFR 240.12d2-2(b)
Amy Horton
Hearings Advisor
2018-07-19
EX-99.25
2
argsdelistreason.txt
Delisting Determination,The Nasdaq Stock Market, LLC,
July 19, 2018, Argos Therapeutics, Inc. The Nasdaq
Stock Market, Inc. (the Exchange) has determined to remove
from listing the common stock of Argos Therapeutics, Inc.
(the Company), effective at the opening of the trading
session on June 18, 2018. Based on review of information
provided by the Company, Nasdaq Staff determined that the
Company no longer qualified for listing on the Exchange
pursuant to Listing Rule 5450(b)(2)(A).
The Company was notified of the Staffs determination on
October 26, 2017. The Company appealed the determination
to a Hearing Panel. Upon review of the information provided
by the Company, the Panel issued a decision dated
January 17, 2018, granting the Company continued listing
pursuant to an exception that included several milestones
that the Company was required to meet, towards the toal
of regaining compliance with Listing Rules 5450(b)(2)(A),
5450(b)(2&3)(C) and 5450(a)(1). However, the Company was
unable to meet the exception milestones as required.
On April 23, 2018, the Panel issued a final delisting
determination and notified the Company that trading in the Companys
securities would be suspended on April 25, 2018.
The Company did not request a review of the Panels decision
by the Nasdaq Listing and Hearing Review Council. The
Listing Council did not call the matter for review.
The Panels Determination to delist the Company
became final on June 7, 2018.